Uma Sinha, Ph.D.
Chief Scientific Officer
Uma Sinha, Ph.D., is the chief scientific officer of Eidos Therapeutics. She has extensive experience in discovery and preclinical development of agents targeting pathogenesis of hematologic, cardiovascular, and inflammatory diseases. Before joining Eidos, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics. Previously, she was vice president and head of biology at Portola Pharmaceuticals and held senior research positions at Millennium Pharmaceuticals and COR Therapeutics. During her tenure at COR, Dr. Sinha and her team were responsible for the initiation and progression of factor Xa inhibitor programs that led to the development of betrixaban, which is currently awaiting FDA approval as the first anticoagulant for extended duration venous thromboembolism prophylaxis in acute medically ill patients. Dr. Sinha has led the development of five novel agents currently in advanced clinical trials or awaiting FDA approval.
She has authored or co-authored 70 scientific articles in peer-reviewed journals and is a named inventor in 25 issued U.S. patents. Dr. Sinha holds a Ph.D. in biochemistry from the University of Georgia and received her postdoctoral training in pathology and chemistry at the State University of New York, Stony Brook.